Novel methods of local control for sarcomas are needed. We investigated the antitumor effect of two related herpes simplex virus (HSV) mutants, NV1020 and NV1066, on human rhabdomyosracoma cells and xenografts. Cell death correlated with virus replication and apoptosis in cultured cells and tumors. Complete regression was seen in all tumors o250 mm 3 following a single
S
oft tissue sarcomas occur in all age groups, and can arise at virtually any body site. The ''local'' treatment of sarcomas is mainly surgical, with adjuvant radiation used selectively for high-grade, incompletely resected lesions. An inadequate surgical margin is the major risk factor for local recurrence. 1, 2 In adult patients, chemotherapy has been shown to be of only mild benefit, delaying the time to recurrence but not affecting overall survival. 3 For localized extremity lesions, there have been a number of advances including limb-sparing surgical procedures and the identification of adverse risk factors, but there has been no improvement in survival (65% disease-free survival, 19% local recurrence) in the past 20 years. 4 Retroperitoneal lesions are particularly troublesome, as they typically involve adjacent nerves, major blood vessels, and viscera, making their resection difficult. Local recurrence rates for retroperitoneal lesions range from 40 to 70%, and death is most often a result of local progression. 5 Sarcomas appearing in childhood also pose therapeutic dilemmas. Although chemotherapy has been very effective in improving the survival of children with some types of soft tissue sarcomas such as localized rhabdomyosarcoma, most other types are resistant to chemotherapy and irradiation. 6 In addition, surgical resection may be disfiguring, particularly for sarcomas of the head and neck. Furthermore, irradiation doses required for adequate tumor therapy may not be tolerated by normal tissues, especially for intra-abdominal, intrathoracic, or craniofacial locations. 7 Tumors in patients o1 year old pose unique problems and have a higher rate of local recurrence, likely due to a reluctance to subject them to irradiation. 8 Finally, radiation therapy can be complicated in children by subsequent bone growth deformities, endocrinologic disturbances, and secondary cancers. [9] [10] [11] [12] Therefore, there remains a need for new methods of local control for sarcomas, both in adults and children.
The administration of oncolytic viruses by direct intratumoral injection or by systemic administration represent emerging anticancer strategies. Mutated herpes simplex virus (HSV) derivatives have been shown to be safe in phase I human clinical trials by both intracranial 13, 14 and intrahepatic artery administration. 15 We and others have previously shown that cell lines derived from sarcomas occuring in both adults and children are sensitive to lytic infection by HSV mutants including those derived from rhabdomyosarcoma, osteosarcoma, and malignant fibrous histiocytoma. 16, 17 A number of different HSV mutants have been engineered to selectively replicate in tumor cells based on deletions of critical genetic functions that are dispensable for viral replication in cancer cells (for reviews, see Varghese et al  18 and Arceci  and Cripe   19 ). For example, NV1020 20 and NV1066 21 are deleted for one copy of the diploid ''neurovirulence'' gene encoding ICP34.5. Viral infection activates the doublestranded RNA inducible protein kinase (PKR) pathway to terminate protein synthesis and prevent viral replication. During infection with wild-type HSV1, ICP34.5 reverses this antiviral defense mechanism, allowing protein synthesis to continue and virus replication to proceed. In many cancer cells, the PKR pathway is defective, allowing lytic infection by ICP34.5 mutant viruses. 22 The mechanism of cell death by HSV infection has been examined in both cultured cells and animal tumor models. HSV type 1 infection causes cell death by both apoptotic and nonapoptotic pathways, which vary in a cell linedependent manner. 23 It is well established that the normal cellular response to HSV1 infection is the activation of apoptotic pathways that restrict virus replication. As a compensatory mechanism, several early viral proteins interfere with apoptosis, thus allowing efficient virus production (reviewed in Aubert and Blaho 24 ). Infection with replication-defective HSV recombinants that do not express early proteins causes high levels of cellular apoptosis in a cell-type-specific manner. 25 Uninfected neighboring cells may also undergo apoptosis following injection of some cell lines with NV1066, 26 and it has been proposed that such apoptosis might limit virus spread. Tumors injected with oncolytic HSV mutants often have regions of necrosis associated with HSV-infected cells, [27] [28] [29] [30] [31] and in some cases there is a concomitant increase in apoptotic cells. 32 In syngeneic model systems, viral infection also stimulates tumor infiltration by both innate and adaptive immune cells, suggesting a multifactorial antitumor effect. 33 Infection with oncolytic HSVs has been shown to be lytic for a variety of cancer cell types. In many studies with rodent tumor models or human tumor xenografts, significant anticancer effects have been observed following local (intratumoral), regional (intraperitoneal, intraportal vein, or intra-arterial), and systemic (intravenous) viral administration. The most dramatic effects have been seen following direct intratumoral administration, likely due to higher delivery of virus to tumor sites. Therefore, there is much promise for oncolytic HSVs to be useful in achieving local control for solid tumors.
Local control of sarcomas usually involves surgical resection or radiation of a bulky tumor mass. . We used a high-risk alveolar rhabomyosarcoma model to determine the effect of oncolytic HSV injections on large human tumor xenografts. Our results suggest that oncolytic viral therapy can indeed be useful for the control of large tumors, and that the antitumor effect can be improved through wider geographical distribution of injected virus, achievable by dividing the dose into multiple fractions.
Results

Cytotoxicity, virus production, and apoptosis in rhabdomyosarcoma cells
We have previously shown a number of sarcoma cell lines are highly susceptible to lytic infection by NV1020 including the high-risk alveolar rhabdomyosarcoma cell line Rh18A. 16 In order to better track virus infection following intratumoral injection, we tested the sensitivity of Rh18A cells to infection by NV1066, a mutant similar to NV1020 that expresses the enhanced green fluorescent protein (eGFP). 21 The cytotoxicty dose-response curves in Rh18A cells for each virus were essentially identical with a lethal concentration for 50% of the cells by 6 days after infection of o0.005 plaque forming units (PFU)/cell (Fig 1a) . In addition, virus production in Rh18A cells following infection at a multiplicity of infection (MOI) ¼ 1 was also similar for the two viruses reaching levels B1.5 logs above baseline by 48 hours (Fig 1b) . Therefore, these two viruses were used in subsequent experiments interchangeably, depending on the need for virus transgene visualization.
We next sought to determine the role of apoptosis in cell death following productive virus infection in these cells. Rh18A cells in culture were tested by flow cytometry for activated caspase-3 following infection with NV1020. Cells were exposed to virus (MOI ¼ 1) and at various times after infection were fixed, permeabilized, and stained with anti-activated caspase-3 antibody. As a positive control for apoptosis, marked and increasing caspase activation was observed after exposure of cells to camptothecin at 24 and 48 hours, falling somewhat at 72 hours likely due to the death of apoptotic cells (Fig 2) . Following infection with NV1020, a small number of cells showed detectable caspase-3 activation at 24 and 48 hours (2 and 6%, respectively), which significantly increased at 72 hours (41%). The HSV1 replication cycle is typically completed by 18 hours, 24 and we detected significant virus production and cytotoxicity at 24 and 48 hours (Fig 1) . Thus, the biological significance of the late apoptosis we observed at 72 hours is unclear, but does not appear to inhibit virus production.
Single intratumoral injections
To determine the antitumor effect of virus injections in vivo, we first used a model of subcutaneous human alveolar rhabdomyosarcoma tumors derived from Rh18A. In this model, only 60% of mice develop tumors, usually detectable 4-6 weeks following subcutaneous injection of 5 million cells. The cells rarely metastasize, so animals can survive with very large primary tumors. Once established, tumors grow rapidly, doubling their volume in 5-10 days (Fig 3a) .
Tumors ranging in volume from 130 to 230 mm 3 were injected with 1 Â 10 7 PFU per 100 mm 3 tumor volume and monitored for growth. Control tumors injected with UVinactivated virus showed similar growth kinetics to uninjected and phosphate-buffered saline (PBS)-injected tumors (data not shown); therefore, PBS was used as a negative control to conserve virus stocks. Tumors were considered to have progressive disease (PD) if they grew 450% in volume, stable disease (SD) if their size remained within 750% of the original volume, a partial response (PR) if they shrunk to o50% of the original volume, and a complete response (CR) if they became undetectable. While 5/5 small tumors (o250 mm 3 ) injected with PBS had PD (Fig 3a) , all 10 injected with NV1020 showed a CR (Fig 3b) . All tumors initially diminished in size with similar kinetics, and the most rapidly responding tumor disappeared within 3 weeks. Several of the tumors remained small palpable masses for a period of time, but all eventually disappeared by 8 weeks. The response of larger tumors, ranging in size from 300 to 725 mm 3 , was also determined following a single virus injection on day 0 (Fig 3c) . While a majority of the tumors responded (6/8 CR or PR), two of these eventually progressed, yielding a final durable CR rate of 50% (4/8). These results suggest that the virus dose as given was not sufficient to completely control the growth of large tumors.
To ensure that the permissiveness of Rh18A tumors to HSV infection was not unique to cells passaged in tissue culture, we also tested A3626, a human tumor xenograft derived from a primary embryonal rhabdomyosarcoma. A3626 has never been grown in tissue culture, having been propagated solely in nude mice. 48 Small A3626 tumors were not studied because when these xenografts are propagated by tissue explant, mincing, and reimplantation, the resulting lump is equivalent in size to a small tumor. Not all of these implanted tumors continue to grow, so only those tumors with obvious growth were used for these experiments. Injection of large A3626 tumors (250-500 mm 3 ) with PBS showed similar growth kinetics to PBS-injected Rh18A tumors, with all having PD (Fig 3d) . Injection with virus resulted in 3/7 CR, 2/7 PR, 1/7 SD, and 1/7 PD (Fig 3e) . These data are consistent with those obtained in the large Rh18A tumors.
Fluorescence microscopy of virus-injected tumors
To visualize the intratumoral fate of virus-infected cells, we analyzed uninjected tumors and compared them to tumors injected with NV1066 72 hours postinjection by fluorescence microscopy (Fig 4) . Uninjected control tumors showed no detectable green fluorescence and a uniform population of healthy appearing nuclei by staining with 4 0 -6-diamidine-2 0 -phenylindole (DAPI, data not shown). In virus-injected tumors, most of the eGFP signal appeared in clusters of small, punctate foci consistent with cellular debris due to a local virus infection (Fig 4a) . Nuclear staining with DAPI revealed intact, healthy appearing nuclei surrounding the scattered eGFP signal, suggesting that uninfected neighboring cells were unaffected (Fig 4b, c) . Only a relatively few intact infected cells were found, which contained homogeneous green fluorescence (Fig 4d) ; in a majority of these cells, there was either no nucleus visible or only a nuclear remnant on DAPI stain (Fig 4e, f) . These data are consistent with infected cells undergoing apoptosis and nuclear disintegration.
Single vs. fractionated injection: intratumoral virus distribution, transduction, and virus production
We next sought to determine whether alternative delivery strategies might improve intratumoral virus production and distribution and thus enhance the antitumor effect for large tumors. Based on our different response rates for small vs. large tumors, we postulated that the limiting feature of direct intratumoral injections in large tumors may be an insufficient access of tumor cells to virus. We hypothesized that fractionating the virus dose into several smaller injections might increase the number of cells exposed to virus and thus might yield improved results with large tumors.
To quantitate the number of transduced cells in tumors given a dose of NV1066 as a single 100 ml injection compared with those given five 20 ml fractions (upper left, upper right, lower left, lower right, and top), tumors were harvested and analyzed for eGFP expression by flow cytometry 16 hours after the different virus injection methods were used. A relatively early time point was used for these experiments to determine the effect of the initial transduction rather than including subsequent rounds of virus replication. We did not find a significant difference in the percentage of transduced cells between the two methods of virus administration (Fig 5a) . These data suggest that fractionated dosing does not expose a measurably higher number of cells to the initial virus infection. As a corollary to these data, we also measured viral transgene expression and virus production at later times after virus injection. We used the virus G207, an oncolytic HSV mutant expressing b-galactosidase, to facilitate accurate quantitation of viral transgene expression at 48 hours. We did not observe any difference in viral gene expression between tumors given a single or a fractionated injection (Fig 5b) .
Lysates from injected tumors were also tested by plaque assay for infectious virus at 5 minutes (early baseline), 3 hours (late baseline), and 96 hours (Fig 5c) . When compared with 5 minutes postinjection, overall there was less detectable virus in the tumors at 3 hours postinfection, likely due to adsorption of virus onto and into cells, thus inactivating virus particles. At 96 hours postinjection, however, there was a 2-3 log increase in virus titers, confirming intratumoral virus replication. We found equal or less virus produced at each time point in the tumors given a fractionated virus injection compared with those given a single injection. These data clearly suggest that fractionated dosing does not result in increased intratumoral virus production compared to single dosing.
To compare intratumoral geographic virus distribution using the two different administration methods, we analyzed tumors on a macroscopic level for eGFP expression 72 hours following injection with NV1066 using a fluorescence dissecting microscope (Fig 5d) . In these experiments, eGFP expression appeared more widespread in the tumors given a fractionated injection than those given a single injection. Microscopic quantitation of eGFP on tumor sections was not possible because, as shown in Figure 4 , the eGFP signal was scattered inhomogeneously, primarily in cellular debris.
Antitumor efficacy of fractionated intratumoral virus injections
Although fractionated injection did not yield increased virus transduction, transgene expression, or production, the above data suggest that it did lead to improved intratumoral virus distribution. Therefore, we tested the antitumor effect of fractionated injection on the growth of large tumors, 570-1200 mm 3 . We first divided the dose into 10 equal fractions and injected NV1020 into tumors three times weekly (10 doses). Six of seven tumors up to 1100 mm 3 had a complete response (Fig 6a) . One tumor had a very good partial response, and then relapsed at a site adjacent to the primary mass that had disappeared. The largest tumor, 1200 mm 3 at the time of injection, showed a period of initial growth followed by shrinkage, but regrew after the injections were stopped. Thus, distributing the virus injections over time appeared to improve the antitumor effect, but did not completely eradicate large tumors.
Because frequent, repeated injections may not be clinically feasible or desirable, we sought to determine if fractionated injections on the same day would also yield superior results to single injections. Therefore, the same total dose of NV1066 was administered in five fractions to seven large tumors, 490-695 mm 3 . All had a complete response with similar kinetics to previous experiments seen with small tumors, disappearing within 3-5 weeks (Fig 6b) . The response rate (CR þ PR þ SD) for fractionated vs. single injection shown in Figure 1 was statistically significant (P ¼ .05). To confirm the requirement for replication-competent virus, NV1066 was inactivated by ultraviolet (UV) light and given to another cohort of tumors with the same five-fractionated injection scheme (Fig 6c) . All of tumors injected with UVinactivated virus showed progressive disease (P ¼ .003 compared to intact virus in Fig 6b) . HSV-1 expresses a variety of early viral genes that act in part to inhibit the early apoptotic cellular response to infection in order to allow efficient virus production. 24 The apoptosis we observed in infected cells mainly occurred late, after virus release. Thus, we conclude that NV1020 retains the early antiapoptotic phenotype of wild-type HSV-1 and that its replication is not limited by the late cellular apoptosis.
We did not find an increase in numbers of transduced cells, viral gene expression, or virus production in tumors following the fractionated dose compared with a single dose. Fractionated injection did result in more widespread intratumoral virus distribution. These data suggest there is a barrier to virus spread when using a single injection that can be overcome by fractionated injection. Based on data in cell culture, it has been proposed that apoptosis of adjacent, uninfected cells might limit virus spread within a tumor. 26 While we found nuclear changes consistent with apoptosis in early infected cells on tumor sections, cells surrounding infected cells or the debris of infected cells (identified by eGFP expression) appeared healthy. It stands to reason that to improve the antitumor effects of oncolytic viruses efforts should be focused not only on being able to inject higher virus doses but also on achieving better initial virus distribution. Whether fractionated dosing will also enhance antitumor efficacy in immunocompetent settings is not yet known.
A recent mathematical approximation of oncolytic virus infections predicted that an initial wider distribution of virus throughout a tumor mass would be more effective at tumor eradication than a single, central injection. 49 Our data demonstrating an improved antitumor effect with fractionated dosing support this prediction.
In confirmation of our previous results, 16 the multimutated virus, G207, was recently reported to be oncolytic for rhabdomyosarcoma cells in culture by Cinatl et al. 17 They also found an antitumor effect with direct intratumoral injections in nude mice. In their study, however, only 25% of relatively small tumors (B100 mm 3 ) directly injected with G207 were cured using two injections of 1 Â 10 7 PFU on days 0 and 4. Two possible explanations for their lower cure rates are that either the cells they tested are less susceptible to HSVinduced killing or the virus they used is less potent than NV1020. In culture, the cells they used appeared to have similar oncolytic sensitivity as we observed with Rh18A, suggesting that their lower cure rate was not due to the use of more resistant cell lines. The more likely explana- Figure 6 Effect of fractionated intratumoral virus injections on growth of large rhabdomyosarcoma xenografts. The same injected total virus dose used in Figure 2 was fractionated over 10 doses given three times weekly (a, NV1020) or over five doses given on day 0 (b, NV1066). The relapsed tumor in panel (a) (black squares) was at a site adjacent to the originally injected tumor. For the data in panel (a), P ¼ .01 vs. PBS-injected tumors (Fig 1a) ; for panel (b), P ¼ .001. For comparison with panel (b), fractionated dosing of UVinactivated virus on day 0 was also administered to tumors of similar size (c, UV-NV1066); for panel b vs. c, P ¼ .003. tion is thus difference in virus potency, since others have found G207 to be less potent than NV1020. 50 Importantly, Cinatl et al also demonstrated an antitumor effect following intravenous administration of virus that was potentiated by the addition of vincristine. Others have found a synergy between G207 and irradiation, at least in part due to the radiation-induced upregulation of cellular ribonucleotide reductase. 51 Therefore, oncolytic HSVs may be useful as a treatment for rhabdomyosarcomas and possibly other sarcomas either alone or in combination with chemotherapy and radiation therapy.
In addition to surgery and irradiation, other methods of achieving local control for sarcomas, such as the injection of oncolytic HSVs, are clearly needed. To date, however, tumor regression has only been demonstrated for relative small tumor burdens, limiting enthusiasm for using these agents as a means of local control for bulky disease. Our data with relatively large sarcoma xenografts suggest that oncolytic virus therapy may be useful for the local control of soft tissue sarcomas. The fact that oncolytic herpes viruses can spread via lymphatics to regional metastases is also encouraging for their use as a means of locoregional treatment. 21 While virus could be administered directly to a tumor, our study suggests that administration of virus might best be performed intraoperatively, in conjunction with a debulking procedure, to maximize geographic distribution of virus throughout the tumor. Alternatively, if an appropriate tumor vascular supply can be identified, widespread intratumoral distribution of virus might also be achievable through catheter-directed intra-arterial administration.
Materials and methods
Cells and tissues
Animal studies were approved by the Cincinnati Children's Hospital Institutional Animal Care and Use Committee, and the use of human tissues was approved by the Institutional Review Board. Human rhabdomyosarcoma xenografts were generated using Rh18A cells (kindly provided by Frederick Barr, University of Pennsylvania, Philadelphia, PA) and the primary xenograft A3626 tissue suspension (obtained from the xenograft tumor bank at Cincinnati Children's Hospital Medical Center, Cincinnati, OH). The Rh18A line expresses the PAX3-FKHR fusion gene 52 that characterizes alveolar rhabdomyosarcoma. Rh18A cells were grown in RPMI media with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. Rh18A xenografts were established by subcutaneous injection of 5.0 Â 10 6 cells in 150 ml with either 0 or 33% Matrigel (Becton Dickenson, Bedford, MA) in 4-6-week old female Balb/c athymic nude mice (Harlan Sprague Dawley, Indianapolis, IN or NCI, Frederick, MD). A3626 primary xenografts were established by subcutaneous injection of 250 ml A3626 tissue suspension in serum-free media (prepared from an A3626 xenograft tumor). Rabbit skin cells (RSC) were a gift from Nancy Sawtell (Cincinnati Children's Hospital Research Foundation, Cincinnati, OH) and were grown in MEM plus 10% FBS supplemented as above.
Viruses
Viruses were provided by MediGene, Inc. (San Diego, CA). Briefly, NV1020 (derivative of R7020, strain F) is deleted for the internal repeats, with insertion of HSV-2 glycoprotein sequences, and is haplotype for ICP34.5; 20 the stock concentration was 4.4 Â 10 8 PFU/ml. NV1066 is similar to NV1020 except that it contains the gene encoding eGFP; 21 the stock titer was 1.83 Â 10 10 PFU/ ml. G207 is an oncolytic HSV derived from strain F, deleted for ICP34.5 and contains an insertion mutation of the bacterial b-galactosidase gene in ICP6; 53 the stock titer was 2.5 Â 10 9 PFU/ml. Virus was injected on day 0 directly into tumors at a total dose of 1 Â 10 7 PFU per 100 mm 3 of tumor volume either as a single dose or split into fractions at different sites or times as indicated in the figures. In Figure 5a -d, a total dose of 1 Â 10 7 PFU in 100 ml was used for all tumors. Data in Figure 3 are from tumors injected with either NV1020 or NV1066. To obtain a replication-defective virus, NV1066 (1.0 Â 10 9 PFU/ml) was exposed to 1.44 x10 6 microjoules of UV using a Stratalinker 1800 (Stratagene, La Jolla, CA). The titer was determined by standard HSV plaque assay to be o10 PFU/ml (48 logs attenuation). Briefly, RSC were seeded at 2 Â 10 5 cells per well (24-well dish) and infected with virus dilutions. After 2 hours, 800 ml of 1 Â MEM with 10% FBS and 1% carboxymethylcellulose (Sigma, St Louis, MO) was overlaid. Plaques were fixed with 0.5% crystal violet (dissolved in 200 ml of 95% ethanol, diluted to 1 l with water) and counted 48 hours postinfection.
Detection of active caspases
5 Â 10 5 Rh18A cells were seeded in six-well plates and infected with NV1020 at 1 PFU/cell. Camptothecin at 57 mM served as a positive control. After 24, 48, and 72 hours cells were harvested, pelleted and washed twice with cold PBS. Caspase-3 activation was detected using an FITC-conjugated antiactive caspase-3 monoclonal antibody apoptosis kit (BD Pharmingen, San Diego, CA). In brief, the cells were permeabilized, washed and incubated with the FITC-conjugated antibody in the dark for 30 minutes at room temperature. Cells were then washed and resuspended using the supplied Perm/Wash buffer. Cells were then analyzed via flow cytometry using the FACS Calibur analyzer (Becton Dickenson, San Diego, CA).
Virus production
Â 10
6 Rh18A cells were seeded in each well (six-well dishes) and allowed to attach for 1 hour. Cells were infected with either NV1020 or NV1066 at 1 PFU/cell. Media and cells were harvested at 1, 24 and 48 hours and subjected to three cycles of freeze-thaw. Cell debris was removed by centrifugation at 3000 g and the supernatants were used to determine viral titer by plaque assay (described above).
Intratumoral viral therapy
Tumors were directly injected with or without virus in 100 ml PBS as a single (1 Â 100 ml dose) or fractionated dose (5 Â 20 ml injections). Tumor volume was estimated by (length Â (width) 2 )p/6. The statistical significance of tumor response was determined by the two-tailed Fisher Exact Test.
Intratumoral virus transgene expression and production
For quantitative b-galactosidase reporter gene expression, tumors injected with G207 were harvested at 48 hours and homogenized in 5 ml Galacto Star kit lysis buffer (Tropix, Bedford, MA). After centrifugation at 3000 g for 10 minutes to remove cell debris, the lysates were assayed for b-galactosidase according to the manufacturer's instructions. Luminescence was measured on a Luminoskan Ascent microplate luminometer (Thermo Labsystems, Helsinki, Finland). For virus production, mice were euthanized by CO 2 asphyxiation and tumors harvested immediately (T ¼ 5 min), 3 hours (T ¼ 3), and 96 hours (T ¼ 96) postinjection with NV1020. Tumors were homogenized in RPMI 1640 media and subjected to three freeze-thaw cycles. Lysates were spun at 3000 g for 10 minutes and supernatants analyzed by plaque assay (described above).
Intratumoral virus distribution
For quantitative FACS analysis, tumors were harvested at 48 hours and sliced and minced between two frosted microscope slides to prepare a tissue homogenate. The homogenate was incubated in RPMI 1640 containing collagenase type I (1.4 mg/ml, Sigma, St Louis, MO) and DNase I (0.3 mg/ml, Sigma) at 371C for 30 minutes and passed through a 70 mm cell strainer. The cells were washed with PBS, suspended in 1 ml PBS containing propidium iodide (0.5 mg/ml) and analyzed by FACS. To visualize virus distribution macroscopically, tumors were harvested at 72 hours, rinsed with PBS and analyzed for eGFP expression using the Leica MZ FLIII fluorescence stereomicroscope (Leica Microsystems, Inc., Bannockburn, IL) at Â 8 magnification with the GFP Plus filter. For fluorescence microscopy, RH18A xenograft tumors were injected intratumorally with a single dose of 1.0 Â 10 7 PFU per 100 mm 3 and harvested at 72 hours postinfection. Tumors were fixed overnight in 30% sucrose containing 4% paraformaldehyde, embedded in M-1 Embedding Matrix (ThermoShandon, Pittsburgh, PA) and frozen overnight at À801C. Frozen tumor specimens were sectioned (8 mm), placed on positively charged Superfrost slides (Fisher Scientific, Pittsburgh, PA), air-dried for 30 minutes and rinsed with PBS three times prior to applying mounting media with DAPI (Vectashield, Burlingame, CA). Sections were analyzed on a Leica DMIRB fluorescence inverted microscope. The eGFP and DAPI pictures of each tumor were then overlaid using Open Lab Software (Improvision, Lexington, MA).
